MA48620A - Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique - Google Patents

Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Info

Publication number
MA48620A
MA48620A MA048620A MA48620A MA48620A MA 48620 A MA48620 A MA 48620A MA 048620 A MA048620 A MA 048620A MA 48620 A MA48620 A MA 48620A MA 48620 A MA48620 A MA 48620A
Authority
MA
Morocco
Prior art keywords
anticholinergic
corticosteroid
adrenergic
beta
preparing
Prior art date
Application number
MA048620A
Other languages
English (en)
Inventor
Alessandro Cavecchi
Cristiana Merusi
Fausto Pivetti
Francesca Schiaretti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA48620A publication Critical patent/MA48620A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA048620A 2017-05-11 2018-05-09 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique MA48620A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17170632 2017-05-11

Publications (1)

Publication Number Publication Date
MA48620A true MA48620A (fr) 2021-04-28

Family

ID=58707344

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048620A MA48620A (fr) 2017-05-11 2018-05-09 Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Country Status (10)

Country Link
US (1) US10350164B2 (fr)
EP (1) EP3621589B1 (fr)
KR (3) KR102637298B1 (fr)
CN (2) CN119656140A (fr)
ES (1) ES2882153T3 (fr)
MA (1) MA48620A (fr)
MX (1) MX374484B (fr)
PL (1) PL3621589T3 (fr)
RU (1) RU2741427C1 (fr)
WO (1) WO2018206619A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206618A1 (fr) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. Procédé de préparation d'une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MX2022003427A (es) 2019-09-24 2022-04-18 Chiesi Farm Spa Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
HRP20140582T4 (hr) * 2009-12-23 2023-06-09 Chiesi Farmaceutici S.P.A. Kombinacijska terapija za copd
LT3019153T (lt) * 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
BR112016029487B1 (pt) 2014-06-30 2022-03-29 Chiesi Farmaceutici S.P.A. Aba para um mecanismo e inalador de pó
CN105982880A (zh) * 2015-03-16 2016-10-05 四川海思科制药有限公司 一种干粉吸入剂药物组合物及其制备方法
JP6942126B2 (ja) * 2015-11-16 2021-09-29 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 抗コリン作用薬、コルチコステロイド及びβ−アドレナリン作用薬を含む乾燥粉末製剤の製造方法
HUE056260T2 (hu) * 2015-11-16 2022-02-28 Chiesi Farm Spa Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására

Also Published As

Publication number Publication date
CN119656140A (zh) 2025-03-21
KR102637298B1 (ko) 2024-02-20
KR20190142769A (ko) 2019-12-27
MX2019012930A (es) 2020-01-14
PL3621589T3 (pl) 2021-12-06
US20180325815A1 (en) 2018-11-15
KR20220155609A (ko) 2022-11-23
US10350164B2 (en) 2019-07-16
KR20240105510A (ko) 2024-07-05
CN110612095A (zh) 2019-12-24
ES2882153T3 (es) 2021-12-01
EP3621589A1 (fr) 2020-03-18
RU2741427C1 (ru) 2021-01-26
MX374484B (es) 2025-03-04
WO2018206619A1 (fr) 2018-11-15
CA3059824A1 (fr) 2018-11-15
BR112019023386A2 (pt) 2020-06-16
EP3621589B1 (fr) 2021-07-07

Similar Documents

Publication Publication Date Title
MA50487A (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EP3486242A4 (fr) Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
EP3406625A4 (fr) Poudre d'oligopeptides de noix, et son procédé de préparation et application associée
EP3453707A4 (fr) Dérivé de benzazépine, procédé pour le préparer, composition pharmaceutique et son utilisation
EP3357491A4 (fr) Composition pharmaceutique contenant un médicament anionique, et son procédé de préparation
GEAP201914678A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
EP3449956A4 (fr) Composition d'hydrogel médical, hydrogel médical, leur procédé de préparation et leur application
MA43242A (fr) Mélange pour traiter des engrais à base d'urée
EP3393647A4 (fr) Procédé d'encapsulation de composés biologiques, thérapeutiques et d'agents d'imagerie solubles
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MA52252A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
EP3404024A4 (fr) Dérivé de quinazolinone, son procédé de préparation, composition pharmaceutique, et applications associées
EP2978423A4 (fr) Nanocomposition stable comprenant de la doxorubicine, procédé pour la préparation de celle-ci, son utilisation et compositions pharmaceutiques contenant celle-ci
EP3012256A4 (fr) Composé hétérocyclique de benzimidazole-2-pipérazine, composition pharmaceutique le contenant, procédé de préparation et d'utilisation associé
MA52437A (fr) Une formulation de poudre sèche contenant un anticholinergique, un corticoïde et un bêta-adrénergique
EP3438105A4 (fr) Composé de diaryl-b-lactame et son procédé de préparation et utilisation pharmaceutique associée
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
EP3750886A4 (fr) Composé de tétrahydroisoquinoléine, son procédé de préparation, composition pharmaceutique le contenant et utilisation associée
EP3398615A4 (fr) Composition pharmaceutique mucoadhésive et son procédé de préparation
MA48621A (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EP3395371A4 (fr) Composé d'inclusion de médicament, composition à base de celui-ci et leur procédé de préparation
EP3650148A4 (fr) Procédé de préparation de poudre magnétique et poudre magnétique
EP3402798A4 (fr) Composés antagonistes du récepteur a3 de l'adénosine, leur procédé de préparation et leur utilisation médicale
EP3305283A4 (fr) Composition pharmaceutique stabilisée et son procédé de préparation